The NHS has started offering a new '1-minute' immunotherapy injection for tens of thousands of cancer patients. Pembrolizumab, now available in an injectable form, reduces treatment time by up to 90% compared to traditional IV infusion, which could take up to two hours.
This rapid jab is effective against 14 different cancer types, including lung, breast, head and neck, and cervical cancers. Approximately 14,000 patients in England start pembrolizumab therapy each year and are expected to benefit from this more convenient option.
The injection is administered either every three weeks as a one-minute jab or every six weeks as a two-minute injection, depending on the cancer type. The drug works by blocking the PD-1 protein, helping the immune system recognize and attack cancer cells.
Peter Johnson, NHS National Clinical Director for Cancer, called the innovation a lifeline, stating it allows patients to spend less time in hospital and more time living their lives. James Richardson, National Specialty Advisor for Cancer Drugs, added that this is a 'win-win' for patients and the NHS, freeing up vital appointments and reducing waiting times.